- Examples
- Tamoxifen, toremifene, raloxifene, clomiphene
- Raloxifene boxed warning
- Blood clots; fatal stroke in high-risk women
- Clomiphene approved for
- Ovulation induction in women
- Use in men
- Off-label or compounded
One receptor, different effects
Estrogen works by binding to receptors in many tissues. SERMs fit the same receptors but switch them on in some places and off in others. The National Cancer Institute describes how drugs like tamoxifen block estrogen in breast cells while acting like estrogen in bone.
That tissue-by-tissue profile is what makes each SERM useful for different jobs, and also what drives its side effects.
Common SERMs and their uses
- Tamoxifen: treats and helps prevent hormone-receptor-positive breast cancer, in women before and after menopause.
- Toremifene: used for breast cancer in postmenopausal women.
- Raloxifene: prevents and treats osteoporosis after menopause and lowers invasive breast cancer risk in some postmenopausal women.
- Clomiphene: helps women who do not ovulate release an egg.
Main risks
Raloxifene carries a boxed warning for blood clots in the legs and lungs and for fatal stroke in women with or at high risk of heart disease; it is often stopped before surgery or long periods of immobility. Hot flashes and leg cramps are common.
Clomiphene can cause flushing, breast discomfort and headache, and visual symptoms such as blurring, spots or flashes need prompt attention. Long courses in women are generally limited.
Why SERMs come up for men
In men, estrogen feeds back to the brain to restrain LH and FSH. A SERM that blocks that feedback can raise LH, which prompts the testes to make more of their own testosterone and can support sperm production. The American Urological Association says clinicians may use SERMs, aromatase inhibitors, hCG or combinations in men with testosterone deficiency who want to preserve fertility.
This use is off-label for clomiphene. Enclomiphene, one component of clomiphene, is not an FDA-approved drug and is available only through compounding. It works best when the problem is secondary hypogonadism, and labs are needed to monitor response.
At HealifyMD
HealifyMD offers a compounded Enclomiphene / DHEA / Boron / Pregnenolone ODT from $129/month, confirmed at your eligibility review. It is not FDA-approved. A licensed clinician reviews your LH, testosterone and health history, explains the evidence and its limits, and monitors your labs if it is prescribed.
Monitoring on a SERM
Follow-up usually includes repeat testosterone and LH, estradiol, and a blood count, along with questions about vision changes, mood and breast symptoms. Report any leg swelling, chest pain or shortness of breath right away.
SERM: common questions
Is a SERM a hormone?
No. SERMs are not estrogen, but they act on estrogen receptors and can have estrogen-like or estrogen-blocking effects depending on the tissue.
Can SERMs treat menopause symptoms?
Most do not, and some cause hot flashes. A few SERM-based products are approved for specific menopause issues, which your clinician can explain.
Why would a man take a SERM instead of testosterone?
A SERM can raise the body's own testosterone while preserving sperm production, which matters for men who want children. It suits secondary hypogonadism best.
Is enclomiphene FDA-approved?
No. It is available only as a compounded medication, which is not FDA-approved and not equivalent to an approved product.
Do SERMs raise blood clot risk?
Some do. Raloxifene and tamoxifen carry known clot risks, so your history of clots matters before starting any SERM.
What is the difference between a SERM and an aromatase inhibitor?
A SERM blocks or mimics estrogen at its receptor, while an aromatase inhibitor reduces how much estrogen the body makes.
Sources
We cite government agencies, professional societies and peer-reviewed research. See our editorial policy.
- Hormone Therapy for Breast CancerNational Cancer Institute
- RaloxifeneMedlinePlus (U.S. National Library of Medicine)
- ClomipheneMedlinePlus (U.S. National Library of Medicine)
- Evaluation and Management of Testosterone Deficiency guidelineAmerican Urological Association